Application of hematopoietic preparation in preparation of intestinal flora regulator
By regulating the intestinal flora through the Shengxuebao preparation, the abundance of harmful bacteria is reduced and the abundance of beneficial bacteria is increased. This solves the mechanism of action of Shengxuebao compound in regulating the intestinal flora, and achieves the balance restoration of the intestinal flora and the therapeutic effect of blood deficiency syndrome.
Patent Information
- Application Number
- CN202411130460.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-16
- Publication Date
- 2024-11-08
AI Technical Summary
The existing technology does not have a study on the mechanism of action of Xuebao compound on intestinal flora, and there is a lack of effective means to regulate intestinal flora.
The active ingredient, Shengxuebao, is provided in combination with pharmaceutically acceptable excipients to regulate the intestinal flora via oral administration, reducing the abundance of Ranunculus, Enterococcus, and Clostridium, while increasing the abundance of Spirochetes, Rombutz, and Lactobacillus.
Shengxuebao compound can effectively regulate intestinal flora, reduce the abundance of harmful bacteria, increase the abundance of beneficial bacteria, restore the balance of intestinal flora, improve blood count and visceral indicators in rats with blood deficiency syndrome, reduce inflammation, and restore hematopoietic function.
Smart Images

Figure CN118903264A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of intestinal flora regulators, and in particular relates to the application of Shengxuebao preparation in the preparation of intestinal flora regulators. Background Art
[0002] The gastrointestinal tract includes most of the microbiome in the human body and is one of the most extensively and deeply studied ecosystems. Many studies have confirmed that the microbial community of the intestinal flora plays a role in maintaining the health of the body
[135] . Its composition is closely related to the host's diet and disease, and has an important impact on the host's physiology and pathology; therefore, the interaction between the microecological flora and the host constitutes a mutually balanced biological homeostasis. For thousands of years, traditional Chinese medicine has been widely used in clinical practice and has played an important role in the treatment of diseases, but the complex mechanism system of traditional Chinese medicine has limited its in-depth development. With the widespread application of intestinal flora in the field of traditional Chinese medicine, a new path has been opened up for studying the metabolism and transformation of traditional Chinese medicine in organisms.
[0003] Shengxuebao mixture is composed of 7 herbs, including processed Polygonum multiflorum, Ligustrum lucidum, mulberry, Ecliptae, Paeonia lactiflora, Astragalus, and Cibotium barometz. It has the effects of nourishing the liver and kidney, replenishing qi and producing blood, and is widely used in clinic for fatigue, dizziness, and tinnitus caused by liver and kidney deficiency and qi and blood deficiency; leukocytopenia caused by radiotherapy and chemotherapy, iron deficiency anemia, and other diseases. However, no relevant research on the mechanism of action of Shengxuebao mixture on intestinal flora has been reported in the prior art. The present invention uses 16SrRNA sequencing technology to explore the effect of Shengxuebao mixture on intestinal flora, thereby providing a new option for regulating intestinal flora. Summary of the invention
[0004] In view of the above technical problems, the purpose of the present invention is to provide the use of Shengxuebao preparation in the preparation of intestinal flora regulators.
[0005] The objective of the present invention is achieved through the following technical solutions: In a first aspect, the present invention provides the use of Shengxuebao preparation in the preparation of an intestinal flora regulator.
[0006] Preferably, the intestinal flora is an abundance of Ranunculaceae, Enterococcus, Clostridium, Spirochete, Rombutsiella, and lactic acid bacteria.
[0007] Preferably, the Shengxuebao preparation is a Shengxuebao mixture.
[0008] The second aspect of the present invention provides an intestinal flora regulator, comprising Shengxuebao mixture as an active ingredient and pharmaceutically acceptable excipients.
[0009] Preferably, the pharmaceutically acceptable excipients include at least one of a solvent, a filler, a buffer, a cosolvent, an antioxidant, an antibacterial agent, an emulsifier or a flavoring agent.
[0010] The third aspect of the present invention provides a method for regulating intestinal flora, including orally taking Shengxuebao mixture to regulate intestinal flora, which is manifested by reducing the abundance of Ranunculaceae, Enterococcus, and Clostridium; and increasing the abundance of Spirochete, Rombutsiella, and lactic acid bacteria.
[0011] Preferably, the oral dosage for humans refers to the contents recorded in the instructions for use of Shengxuebao mixture, or follows the doctor's advice.
[0012] Compared with the prior art, the present invention has the following beneficial effects: The present invention provides the use of a Shengxuebao preparation in the preparation of an intestinal flora regulator. Specifically, the Shengxuebao mixture can reduce the abundance of Ranunculaceae, Enterococcus, and Clostridium; and increase the abundance of Spirochetes, Rombutzia, and lactic acid bacteria. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1 This is the Venny result diagram of the intestinal flora of each group in this embodiment; Figure 2 This is the diversity analysis of the intestinal flora u of each group in this example (ace index; B.chao index); Figure 3 β diversity analysis of intestinal flora in each group in this example (A. PCoA graph; B. ANOSIM graph); Figure 4 is the change in relative abundance of microbial communities at the genus level in each group in this example; Figure 5 The relative abundance changes of the main genera at the genus level in this example; Figure 6 This is the LDALEfSe analysis diagram of each group of intestinal flora in this embodiment; Figure 7 This is the evolutionary branch diagram of the intestinal flora LefSe in this embodiment; Figure 8 The potential correlation between intestinal flora and different biochemical indicators was determined by Spearman correlation analysis in this example. DETAILED DESCRIPTION
[0014] The inventive concept of the present invention will be illustrated below with reference to specific embodiments. Example
[0015] The embodiment of the present invention provides an application of a Shengxuebao preparation in the preparation of an intestinal flora regulator.
[0016] In some embodiments, the intestinal flora is an abundance of Ranunculaceae, Enterococcus, Clostridium, Spirochete, Rombutsiella, and Lactobacillus.
[0017] In some embodiments, the Shengxuebao preparation is a Shengxuebao mixture.
[0018] A preferred embodiment of the present invention also provides an intestinal flora regulator, comprising Shengxuebao mixture as an active ingredient and pharmaceutically acceptable excipients.
[0019] In some embodiments, the pharmaceutically acceptable excipients include at least one of a solvent, a filler, a buffer, a co-solvent, an antioxidant, an antibacterial agent, an emulsifier or a flavoring agent.
[0020] The preferred embodiment of the present invention also provides a method for regulating intestinal flora, including orally taking Shengxuebao mixture to regulate intestinal flora, which is manifested by reducing the abundance of Ranunculaceae, Enterococcus, and Clostridium; and increasing the abundance of Spirochete, Rombutsiella, and lactic acid bacteria.
[0021] In some embodiments, the oral dosage for humans refers to the contents recorded in the instructions for use of Shengxuebao mixture, or follows the doctor's advice.
[0022] In order to further illustrate the beneficial effects of the present invention, the present invention has verified the effectiveness of the beneficial effects of the present invention through animal experiments, as follows:
[0023] 1. Experimental instruments and materials 1.1 Experimental Instruments Instrument Name Manufacturer Specifications GelDocXR+ Gel Imaging Analysis System Bole1708195 QUBIT3.0 LifeInvitrogen / Q33216 Agarose horizontal electrophoresis apparatus Beijing Children's Day DYCP-31CN Small plate centrifuge Hangmiou MINIP2500 PCR Amplifier Jena EasyCycler96 Pure water / ultrapure water preparation instrument Merck Milli-Q Advantage Micro-volume UV spectrophotometer ThermoNanodrop Clean bench Sujing Antai SW-CJ-2FD -20℃ Refrigerator Haier DW-25L262 4℃ refrigerator Haier HYC-391 Refrigerated Microcentrifuge ThermoFRESCO21 SI Vortex Mixer SIVORETX-GENIE2 Mini centrifuge Qilin Bell LX-100 High-throughput tissue grinding instrument TissueLyserII QIAGENTissueLyserII85300 Constant temperature oscillating metal bath ThermoThermoMixerF1.5 1.2 Experimental Reagents name factory Specification dsDNA Quantification Detection Kit Yisheng 12640ES76 N-Lauroyl Sarcosine Sodium Salt Sigma-Aldrich L5125-500G StoolDNAKit OmegaBio-tek D4015-02 1.5ml centrifuge tube WSP KG2211 2ml non-stand-alone centrifuge tube SARSTEDT 72.693 0.1mm quartz sand Biospec 11079101 DL2000Marker takarabio D501A HieffNGSTMDNAselectionBeads Yisheng 12601ES56* TranStartFastPfuDNAPolymerase (contains 2.5mMdNTPs) Beijing Quanshijin AP221-13 50xTAEBuffer Jerry T1082 Agarose BIOWEST G-10 RNase A Yisheng 10407ES80 Trans15kbDNAMarker Beijing Quanshijin BM401 1000ul pipette tip with filter WSP KG1313 1000ul without filter tip WSP KG5313 200ul pipette tip WSP KG1212 10ul pipette tip GEB PT0010-BN 2ml centrifuge tube WSP KG2911 MiseqReagentKitv3600-cycles Illumina MS-102-3003 Blood-producing mixture Tsinghua Deren Xi'an Xingfu Pharmaceutical Co., Ltd. 220823
[0024] 2. Experimental Methods 2.1 Experimental animals and groups Male Sprague Dawley rats were purchased from the Experimental Animal Center of the Air Force Medical University. The standard license number for experimental animals is IACUC-20231256. The body weight is (250±20) g. The temperature and humidity during the feeding process are 22±2℃ and 50-70%, respectively. The rats are then allowed to adapt to the environment and fed for seven days before the next experiment. All animals and operations comply with the relevant regulations on experimental animal ethics and are licensed and approved by the Air Force Medical University Experimental Animal Ethics Review. The clinical medication of Shengxuebao mixture stipulates that the dosage is 15ml / time, three times a day. According to the body surface area of rats and humans, the rat dosage is 5.25ml / kg. The medium-dose group of Shengxuebao mixture is set at 2.62ml / kg, and the low-dose group is set at 1.31ml / kg. The experimental animals were divided into six groups according to the random number table method: blank group (Control), model group (Model group), compound donkey-hide gelatin group (FEJ) 6ml / kg, high-dose group (Shengxuebao mixture-H) 5.24ml / kg, medium-dose group (Shengxuebao mixture-M) 2.62ml / kg and low-dose group (Shengxuebao mixture-L) 1.31ml / kg. The BDS model was established by subcutaneous injection of APH and intraperitoneal injection of CTX. The specific method was as follows: on the basis of the blank control group, the Model group, Shengxuebao mixture group and FEJ group were subcutaneously injected with APH 20mg·kg-1 on the first day, subcutaneously injected with APH 40mg·kg-1 on the fourth day, and intraperitoneally injected with CTX 25mg·kg-1 2h later. The model can be replicated by continuous injection for 4 days. The blank control group was given an equal volume of normal saline injection. Gavage started from the first day, and the total administration was 10d.
[0025] 2.2 Rat 16S rRNA microbial diversity sequencing Rat contents were sampled for intestinal flora sequencing analysis. The 16SrRNA experimental results were filtered and integrated to obtain high-quality sequences that passed the inspection. UPARSE was first used to cluster them into operational taxonomic units (OTUs) for species classification at a similarity level of 97%. The representative sequences of the data OTUs were annotated according to the SILVA database (SSU138), and then taxonomic analysis was performed to obtain species composition information in the samples. Diversity indicators u and β were used to analyze the richness and diversity of intestinal flora. Diversity indices included ACE index and Chao index. Principal coordinate analysis (PCoA) based on Bray-Curtis and unweighted UniFrac distance was used to compare the differences in community structure between two or more groups. The closer the distance between each sample, the more similar the community structure was. Samples with high similarity in species composition structure tended to cluster together, while samples with large differences were relatively far away. Permutational multivariate analysis of variance (PerMANOVA, also called Adonis analysis) was then used to test the significance of differences between groups in the entire microbial community. R software was used to analyze the species composition of each sample at the subordinate level and to draw a bar graph. The relative content of microbial groups between groups was statistically analyzed. The differences between two groups and between three or more groups were analyzed by the nonparametric Mann-Whitney U test and the Kruskal-Wallis rank sum test, respectively. P <0.05 indicates a significant difference. The data were further subjected to linear discriminant analysis effect size (LEfSe) analysis (lefse1.1, https: / / github.com / SegataLab / lefse), which selects bacterial genera with differences between groups at the genus level, and also selects key OTUs with differences between groups at the OTU level through a random forest classifier model. Spearman correlation analysis was then used to determine the potential correlation between intestinal flora and different biochemical indicators. The connection and changes between variables are shown in heat maps. Finally, PICRUSt2 analysis (https: / / github.com / picrust / picrust2 / wiki) was used to predict the functional genes and metabolic pathways of the flora, and LEfSe analysis was used to select metabolic pathways with differences between groups.
[0026] 3. Results 3.1 Effect of Shengxuebao mixture on the intestinal flora structure of rats with blood deficiency syndrome The first is OTU analysis. Based on the OTU abundance of each sample, the common and unique OTUs of each sample or group are calculated. The Venny diagram can well reflect the number of OTUs shared between groups and unique within a group. Sequences with a similarity of more than 97% are grouped to obtain the number of OTUs for each sample and displayed using a Venny diagram, such as Figure 1 As shown. The Venny diagram shows the structural similarity and overlap of species in different groups. A total of 837 OTUs were identified in group C, while 1002 OTUs were identified in group M, indicating that the composition of the intestinal flora was directly affected after modeling. After treatment with FEJ and Shengxuebao Mixture-H, the number of OTUs in FEJ and Shengxuebao Mixture-H decreased to 967 and 914, respectively. Overall, there were 642 OTUs in the C, M, Shengxuebao Mixture-H and FEJ groups, indicating that the intestinal flora of group M changed compared with group C, while the number of OTUs in group Shengxuebao Mixture-H was reduced more than that in group FEJ, and group Shengxuebao Mixture-H was more able to improve this problem.
[0027] 3.2 Effect of Shengxuebao mixture on the diversity of intestinal flora in rats with blood deficiency syndrome Microbial diversity is studied in community ecology. The richness and diversity of microbial communities can be captured by (udiversity), which consists of a series of statistical analysis indices used to estimate species richness and community diversity. Chao1 and Ace are indices that reflect the richness of the microbial community and can reflect the differences in the microbial communities among the four groups. Figure 2 As shown in the figure, the Chao1 and Ace indexes of group M were significantly higher than those of group C, indicating that the diversity and abundance of intestinal flora in rats in group M can be significantly increased, leading to an imbalance in the ecological balance of intestinal flora. After supplementing with Shengxuebao mixture-H and FEJ, the Chao1 and Ace indexes of each group were lower than those of group M, and were close to the levels of group C. This indicates that the diversity of intestinal flora in rats decreased after administration of Shengxuebao mixture. The above results show that compared with group C, the abundance index and diversity index of intestinal flora in rats in group M were significantly increased. Shengxuebao mixture-H and FEJ groups can reduce the abundance index and diversity index of intestinal flora in rats in group M.
[0028] 3.3 Effect of Shengxuebao mixture on β-diversity of intestinal flora in rats with blood deficiency syndrome Different from u-diversity analysis, β-diversity analysis is often used to compare the differences in species diversity among samples, and is a comparative analysis of the composition of microbial communities between samples / sample groups. It includes PCoA analysis, Anosim analysis, etc. PCoA analysis is one of the methods to evaluate β-diversity, which analyzes the intestinal microbiota based on the Bray-Curtis distance matrix. One of them was based on PCoA to study the differences in β-diversity of rat intestinal flora. The results showed that the intestinal flora of rats in group M and group C were significantly separated, indicating that there were significant differences in the flora structure between the two groups. And the flora of group H of Shengxuebao mixture tilted towards normal rats, indicating that the flora structure of group H of Shengxuebao mixture was similar to that of the normal group and the FEJ group, such as Figure 3 As shown in A. Next, a component similarity test is performed to obtain more precise information on whether there are differences between sample groups. Similarity analysis is a non-parametric test used to test whether the differences between two or more groups are significantly greater than the differences within the groups to determine whether the grouping is significant. Figure 3 B shows that the ANOSIM results (pANOSIM=0.001) and R (R=0.286) are between -1 and 1, and R>0, indicating that the differences between groups are greater than the differences within groups. The results of β diversity analysis confirmed that there were significant differences in the structure and composition of the microbiota between group C, group H of Shengxuebao mixture, group FEJ, and group M.
[0029] 3.4 Effect of Shengxuebao mixture on the composition of intestinal microbial community in rats with blood deficiency syndrome According to the OTU annotation results, the relative abundance of species in each sample was counted and plotted at the genus level. The species and proportions with relatively high abundance at different taxonomic levels in the four groups of samples, C, M, Shengxuebao Mixture-H and FEJ, can be intuitively viewed. The results of genus distribution are shown in Figure 1. Figure 4 Compared with group C, there were 3 species increased in group M, namely Ranunculaceae ( Muribaculaceae )( P <0.05), Enterococcus spp. Enterococcus )( P <0.05), Clostridium ( Clostridia_ UCG-014 ). And spirochetes ( Lachnospiraceae_unclassified )、Rombutsiella pneumoniae( Romboutsia )、Lactic acid bacteria( Lactobacillus ) 3 species decreased. Compared with the M group, the Shengxuebao mixture-H and FEJ groups were treated with Ranunculaceae ( Muribaculaceae ), Enterococcus spp. Enterococcus ), Clostridium ( Clostridia_UCG-014 )、Ruminococcus( Ruminococcus ) were all decreased, and spirochetes ( Lachnospiraceae_unclassified )、Rombutsiella pneumoniae( Romboutsia) increased. In addition, it is worth noting that the beneficial lactobacillus ( Lactobacillus ) The number of Figure 5 The results at the genus level of each group showed that many special bacterial species in the intestinal microbiota of rats with blood deficiency syndrome were significantly changed after treatment with Shengxuebao mixture-H group.
[0030] 3.5 Differential species analysis The species composition bar chart analysis was introduced earlier. The results showed the difference in colony composition between group M and group C at the genus level. In order to further analyze the statistical significance of the difference in species at the genus level, differential species screening was performed. LefSe is an analysis method based on effect size linear discriminant analysis (LDA), which mainly combines LDA with non-parametric Kruskal-Wallis and Wilcoxon rank sum tests to determine key biomarkers. This algorithm emphasizes statistical significance and biological relevance. The results of species analysis between groups are shown in the figure below. Figure 6 and Figure 7 As shown, in group C, the Lactobacillaceae ( g_Lactobacillaceae )、Lactic acid bacteria( g_Lactobacillus ) is the dominant species; Enterococcus in group M ( g_Enterococcus )、( g_ Izemoplasmatales ) was the dominant bacterial species; Cyanobacterium spp. ( g_Erysipelatoclostridium ), another genus ( g_Alistipes ) was the dominant bacteria; Ranunculaceae ( g_Muribaculaceae ), Pseudo-Prevotella ( g_Alloprevotella ) are the dominant bacteria.
[0031] 3.6 Correlation analysis between clinical indicators and intestinal flora in rats with blood deficiency syndrome To determine the regulatory mechanism of the microbiota in each group, Spearman correlation analysis was used. Spearman correlation analysis determined the potential correlation between the intestinal microbiota and different biochemical indices. The determined correlations between the variables were displayed using heat maps. Finally, a network revealing the relationship between the intestinal microbiota and related markers was drawn to evaluate the regulatory effect of Shengxuebao mixture on rats with blood deficiency syndrome. After analyzing the relative abundance of specific bacterial communities and related indices such as hematology, the results were shown in Figure 2. Figure 8 As shown in Figure 2, the bacterial group that was significantly positively correlated with the blood coefficient red blood cell (RBC), hemoglobin (HB), hematocrit (HCT), and serum hematopoietic factor EPO was lactic acid bacteria ( Lactobacillus ), Blautia spp. Blautia ), while Ranunculaceae ( Muribaculaceae ), Bacteroides ( Bacteroides ), Clostridium ( Clostridia-UCG-014) was negatively correlated with these four indicators; Renal index is an important indicator for describing blood deficiency rats. After correlation analysis between the renal index and intestinal flora of each group of blood deficiency rats, it was found that Ranunculaceae ( Muribaculaceae ), Bacteroides ( Bacteroides ), Clostridium ( Clostridia-UCG-014 ), etc. The correlation results were consistent with the genus level results, indicating that the peripheral blood picture, EPO level, and kidney index of blood deficiency rats were closely related to the intestinal flora. By analyzing the intestinal flora at the level of specific genus, harmful bacteria also increased in blood deficiency rats, such as Bacteroides ( Bacteroides ), Clostridium ( Clostridia-UCG-014 ) will decrease with the increase of peripheral blood and increase with the increase of renal index. Beneficial bacteria such as lactic acid bacteria ( Lactobacillus ), Blautia spp. Blautia ) will be positively correlated with peripheral blood, EPO and kidney index after administration of Shengxuebao mixture, indicating that after the body restores hematopoietic ability, its intestinal flora may also restore balance. In summary, the treatment of blood deficiency rats by Shengxuebao mixture and its role in blood supplementation and blood production are related to the regulation of the structure and composition of differential flora in the body, and there is a close connection between EPO and kidneys. The production of EPO in adults is mainly through the kidneys, accelerating the production of erythroid progenitor cells, restoring hematopoietic ability and improving the hematopoietic microenvironment in the body. When pathological changes and inflammatory reactions occur in the kidneys, it will directly affect the production of EPO, thereby leading to ischemia and inflammation of the body. Therefore, based on the correlation analysis between intestinal flora, kidneys and EPO, the correlation between intestinal flora and blood deficiency diseases can be further explored.
[0032] 4. Discussion Intestinal microbiota plays an important role in different biological processes and can directly affect the health of the host. In the experiment, we noticed that rats with blood deficiency syndrome had symptoms such as decreased appetite and diarrhea, and the Shengxuebao mixture treatment group could effectively alleviate the above symptoms. Subsequently, we analyzed the intestinal flora of the feces of the four groups of rats to observe whether the Shengxuebao mixture-H group could regulate the diversity of the intestinal flora of blood deficiency syndrome and play a role in blood supplementation and hematopoiesis in the body.
[0033] The effect of Shengxuebao mixture on the intestinal flora structure of rats with blood deficiency syndrome. The diversity and richness of the microbial communities in the four groups were analyzed. The u diversity was analyzed by Chao1 and Ace indicators. It was found that the M group showed an increase in the diversity and richness index of the intestinal flora compared with the C group. The diversity index of the intestinal flora could be effectively reduced after treatment with Shengxuebao mixture and FEJ. After further β diversity analysis of the four groups, this method mainly included PCoA analysis and Anosim analysis. The PCoA results showed that there was obvious microbiome separation between rats with blood deficiency syndrome and the control group, indicating that the intestinal flora induced by blood deficiency syndrome had undergone significant changes. The Anosim analysis results verified that the flora structure composition of the four groups was significantly different, and the differences between the groups were greater than the differences within the groups. In summary, the Shengxuebao mixture group had a better effect on restoring the species diversity and richness of the flora in rats with blood deficiency syndrome.
[0034] The effect of Shengxuebao mixture on the composition of intestinal microbial community in rats with blood deficiency syndrome was studied. The species composition and differential species analysis of the four groups of microbial communities were observed. Shengxuebao mixture can regulate harmful bacteria such as Ranunculaceae ( Muribaculaceae ), Enterococcus spp. Enterococcus ), Clostridium ( Clostridia_UCG-014 )、Ruminococcus( Ruminococcus Ranunculosis ( Muribaculaceae ) is closely related to intestinal inflammatory response. When the intestinal flora was observed after treatment with antibiotics, it was found that Muribaculaceae There was a significant correlation between blood components; Clostridium spp. Clostridia_UCG- 014 ) are common pathogens and pro-inflammatory bacteria. Increased abundance of spirochetes will lead to increased levels of inflammatory factors. Lachnospiraceae_unclassified )、Rombutsiella pneumoniae( Romboutsia ), Lactobacillus ( Lactobacillus ), another genus ( Alistipes )、 Prevotellaceae_NK3B31_group The beneficial bacteria increase, and the study shows that the spirochetes that can produce butyrate ( Lachnospiraceae_unclassified ) is positively correlated with the body's HB level, and can improve the HB level of patients with chronic anemia by regulating butyrate-producing bacteria. Romboutsia ) is a Gram-positive coccus that is often located in the mucosa of healthy people. Romboutsia Increased abundance plays an important role in immune regulation. Lactobacillus) has strong acid resistance in the body. It can still survive in an environment of pH 3.0-4.5, which is not only conducive to the growth and reproduction of probiotics, but also creates a better environment for flora transplantation. Some studies have shown that lactic acid bacteria can regulate the changes in γ-aminobutyric acid signals and restore the side effects such as immunosuppression caused by cyclophosphamide. The results of intestinal flora suggest that in the process of Shengxuebao mixture treating blood deficiency syndrome, its microbial community such as lactic acid bacteria may produce hematopoietic factors and improve anemia. Another genus of Mycobacterium ( Alistipes ) has been shown to play an important role in IDA; Prevotella is a common intestinal symbiotic bacteria in the human body, which can not only digest carbohydrates in food, but also play an anti-inflammatory and metabolic regulating role in the body. The above results show that Shengxuebao mixture can reduce pathogenic bacteria in the body, restore beneficial bacteria, and regulate the diversity of intestinal microbial composition. Therefore, it was found that Shengxuebao mixture regulates blood deficiency rats mainly by reducing inflammation, restoring hematopoietic function, and regulating immune-related flora.
[0035] In summary, this study used the intestinal flora 16SrRNA technology to confirm that Shengxuebao mixture may affect rats with blood deficiency syndrome by affecting the composition and structure of intestinal microorganisms. Rats with blood deficiency syndrome can affect the hematopoietic system, increase the level of inflammation, damage the intestinal mucosal barrier, and cause an imbalance in the intestinal flora of rats. Supplementation of Shengxuebao mixture can effectively improve the blood and visceral indicators of rats with blood deficiency syndrome. In addition, Shengxuebao mixture affected the diversity and richness of microorganisms, changed the community structure, and alleviated the imbalance of microbiota caused by blood deficiency syndrome. The levels of beneficial and harmful bacteria were regulated, and the differences in intestinal flora between rats with blood deficiency syndrome and normal rats were narrowed, so that the changes in flora were restored and close to normal levels.
[0036] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. Application of Shengxuebao preparation in the preparation of intestinal flora regulators.
2. The use according to claim 1, characterized in that: The intestinal flora includes Ranunculaceae, Enterococcus, Clostridium, Spirochete, Rombutsiella and lactic acid bacteria.
3. The use according to claim 1, characterized in that: The Shengxuebao preparation is Shengxuebao mixture or Shengxuebao granules.
4. An intestinal flora regulator, characterized in that The invention comprises the Shengxuebao mixture as an active ingredient and also comprises pharmaceutically acceptable auxiliary materials.
5. The intestinal flora regulator according to claim 4, characterized in that The pharmaceutically acceptable excipients include at least one of a solvent, a filler, a buffer, a cosolvent, an antioxidant, an antibacterial agent, an emulsifier or a flavoring agent.
6. A method for regulating intestinal flora, characterized in that: This includes oral administration of Shengxuebao mixture to regulate intestinal flora, which is manifested by reducing the abundance of Ranunculaceae, Enterococcus, and Clostridium; and increasing the abundance of Spirochete, Rombutsiella, and lactic acid bacteria.
Citation Information
Patent Citations
Application of traditional Chinese medicine extract precipitate
CN114947004A
Application of Qigui Shengbai capsule in preparation of medicine for regulating intestinal microbial flora disorder
CN117482138A
